# NCT05029882 (NCT05029882)

> Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05029882
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer
- Interventions: ABBV-400; Trifluridine/Tipiracil; Bevacizumab
- Enrollment: 520
- Primary outcome: Objective Response Rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05029882